Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epoetin alfa + vadadustat
- Development stage
- Unknown
- Lead developer
- Akebia Therapeutics
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
The combination of **epoetin alfa** (Epogen) and **vadadustat** (Vafseo) refers to a clinical regimen evaluated in the Phase 3 VOTE trial. Epoetin alfa is a recombinant human erythropoiesis-stimulating agent (ESA) that acts as an agonist of the erythropoietin receptor to stimulate red blood cell production. Vadadustat is an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PHD). By inhibiting HIF-PHD, vadadustat stabilizes HIF-alpha, simulating the body's natural response to hypoxia and stimulating endogenous erythropoietin production. The VOTE study specifically assessed the safety and efficacy of a phased transition from intravenous epoetin alfa to thrice-weekly oral vadadustat in adult patients with anemia secondary to chronic kidney disease (CKD) who were receiving in-center hemodialysis.
- Brand names
- Vafseo
- Other names
- Vadadustat for Anemia in Hemodialysis PatientsVOTE trial context
02
Targets
PHD3 (Prolyl hydroxylase domain-containing protein 3)PHD1 (Prolyl hydroxylase domain-containing protein 1)EGLN1 (Prolyl hydroxylase domain-containing protein 2)Erythropoietin Receptor
Beyond the preview
Go deeper on epoetin alfa + vadadustat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epoetin alfa + vadadustat.